Literature DB >> 28509190

Tophaceous pseudogout in a patient undergoing peritoneal dialysis.

Rika Jimbo1, Hidekazu Iida2, Yoshitaka Ishibashi2.   

Abstract

Calcium pyrophosphate dihydrate deposition disease (pseudogout) is a crystal arthritis characterized by pyrophosphate dihydrate crystal deposition in the articular cartilage or synovium. In chronic kidney disease patients, the major causes of crystal arthritis are calcium oxalate crystals and basic calcium phosphate crystals. However, pseudogout is apparently infrequent among such patients. This report describes a rare case of tophaceous pseudogout (tumoral form of pseudogout) involving the hip joint in a peritoneal dialysis patient, as revealed by CT scan and synovial fluid aspiration. Fluid aspiration and oral NSAIDs improved the clinical symptoms. This report is the first to describe tophaceous pseudogout in a peritoneal dialysis patient, which suggests that pseudogout should be suspected in dialysis patients with unexplained arthritis.

Entities:  

Keywords:  Calcium pyrophosphate dihydrate deposition disease; Chronic kidney disease; Peritoneal dialysis; Pseudogout

Year:  2014        PMID: 28509190      PMCID: PMC5413660          DOI: 10.1007/s13730-013-0107-9

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  11 in total

1.  Pseudogout: a cause of acute arthritis of the right ankle in a uremic patient.

Authors:  S I Lee; W H Yoo; Y B Jang; K P Kang; S Lee; W Kim; S K Park
Journal:  Clin Nephrol       Date:  2006-10       Impact factor: 0.975

2.  Normal peritoneal histology after ten years of peritoneal dialysis in a contemporary Japanese patient.

Authors:  M Tsukamoto; Y Ishibashi; Y Takazawa; Y Komemushi; H Kume
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

3.  Radiologic features of a pyrophosphate-like arthropathy associated with long-term dialysis.

Authors:  E M Braunstein; K Menerey; W Martel; R Swartz; I H Fox
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

4.  The arthropathy of maintenance intermittent peritoneal dialysis.

Authors:  A Chalmers; W J Reynolds; D G Oreopoulos; H E Meema; H Meindok; G A deVeber
Journal:  Can Med Assoc J       Date:  1980-10-07       Impact factor: 8.262

5.  EULAR recommendations for calcium pyrophosphate deposition. Part II: management.

Authors:  W Zhang; M Doherty; E Pascual; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; T Bardin
Journal:  Ann Rheum Dis       Date:  2011-01-20       Impact factor: 19.103

6.  European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.

Authors:  W Zhang; M Doherty; T Bardin; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; E Pascual
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

7.  Acute pseudogout in chronic renal failure.

Authors:  M H Ellman; N L Brown; C A Katzenberg
Journal:  Arch Intern Med       Date:  1979-07

8.  Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.

Authors:  Nadia Announ; Gaby Palmer; Pierre-André Guerne; Cem Gabay
Journal:  Joint Bone Spine       Date:  2009-03-16       Impact factor: 4.929

9.  Tophaceous pseudogout (tumoral calcium pyrophosphate dihydrate crystal deposition disease).

Authors:  T Ishida; H D Dorfman; P G Bullough
Journal:  Hum Pathol       Date:  1995-06       Impact factor: 3.466

10.  Acute pseudogout arthritis in a patient with chronic renal failure: a case report.

Authors:  N Yildiz; F Ardic; O Ercidogan; S Coban
Journal:  Clin Nephrol       Date:  2008-11       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.